June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Water-dispersible hesperetin prevents ganglion cell loss in the retina after retinal ischemia reperfusion injury
Author Affiliations & Notes
  • Akito Shimouchi
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Harumasa Yokota
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Taiji Nagaoka
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Shinji Ono
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Hiroko Takumi
    Institute of Health Science, Ezaki Glico Co., Ltd, Osaka, Japan
  • S.Priya Narayanan
    Vascular Biology Center, Medical College of Georgia, Augusta, Georgia
  • Ruth Caldwell
    Vascular Biology Center, Medical College of Georgia, Augusta, Georgia
    VA Medical Center, Augusta, Georgia
  • Akitoshi Yoshida
    Ophthalmology, Asahikawa Medical University, Asahikawa, Japan
  • Footnotes
    Commercial Relationships Akito Shimouchi, Ezaki Glico Co. (F); Harumasa Yokota, None; Taiji Nagaoka, None; Shinji Ono, Kaken Pharmaceutical Co.,Ltd. (F); Hiroko Takumi, Ezaki Glico.co.jp (E); S.Priya Narayanan, None; Ruth Caldwell, None; Akitoshi Yoshida, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6351. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akito Shimouchi, Harumasa Yokota, Taiji Nagaoka, Shinji Ono, Hiroko Takumi, S.Priya Narayanan, Ruth Caldwell, Akitoshi Yoshida; Water-dispersible hesperetin prevents ganglion cell loss in the retina after retinal ischemia reperfusion injury. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6351. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The citrus flavonoid hesperetin (Hpt) has been shown to improve retinal blood flow and enhance recovery of retinal function after ischemic injury in rats. The aim of this study was to determine whether water-dispersible Hpt could prevent degeneration of ganglion cell neurons in a mouse model of retinal ischemia reperfusion (I/R) injury and to examine the mechanisms of its actions.

Methods: Retinal I/R injury was induced in C57BL/6 mice by increasing the intraocular pressure (IOP) to 110 mmHg for 40 minutes followed by reperfusion. The contralateral eyes served as controls. The mice received daily intraperitoneal injection with either normal saline (NS, 0.3ml/) or Hpt (200mg/kg/) until sacrifice. The mice were sacrificed at 6h, 24h and 7 days after I/R. The whole mount retinas were immunostained with NeuN antibody to detect surviving neurons in the ganglion cell layer at 7 days after I/R. Western blotting was performed to examine the expression of molecules that initiate or promote apoptosis at 6h after I/R.

Results: I/R resulted in a 37% reduction in the number of ganglion cells compared to the fellow eyes in the mice treated with NS, whereas the number of NeuN positive cells in the mice treated with Hpt was reduced by only 5% (p<0.01). At 6 hours after I/R the expression of heme oxygenase-1 (HO-1) and phosphorylation of ERK and p38 MAP kinase were significantly increased in the retina treated with NS, whereas bcl-2 was decreased. In contrast, I/R-induced alteration of those molecules at 6 hours after I/R was markedly attenuated in the mice treated with Hpt.

Conclusions: Our data demonstrate that Hpt protects ganglion cell layer neurons from I/R injury. A marker of oxidative stress, HO-1, and apoptosis signaling pathway indicators, p-ERK, p-p38 MAP kinase, were suppressed by the administration of Hpt whereas a survival pathway indicator, bcl-2, was increased. Thus, water-dispersible hesperetin may provide a promising treatment for ischemic retinopathy.

Keywords: 615 neuroprotection • 572 ischemia • 531 ganglion cells  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×